About this trial
The present clinical study has been designed to evaluate the effect of Collavant® n2 at a daily dose of 40 mg on joint function and performance in healthy, amateur male runners with exercise-induced knee discomfort.
Eligibility criteria
Qualifiers
Healthy physically active male adults (amateur runners) with exercise-induced joint discomfort, aged between 40 and 65 years
Activity level: Amateur runners who train regularly a minimum of 150 minutes per week, divided into 2 or more sessions per week during at least 3 months. Principally, subjects training for popular running events of 10 Kms.
Joint discomfort after activity: Self-reports target knee discomfort after training by a score of at least 20 mm VAS at screening. Discomfort persistent for at least 2w.
Be willing to refrain from starting any new dietary supplements during the entire study that have any underlying joint benefits (collagen, glucosamine, chondroitin, MSM, Hyaluronic Acid, Turmeric, Natural Eggshell Membrane, Omega-3 fatty acids, PEA, Boswellia,..). If any of these supplements (except collagen) or any other dietary supplement has been taken consistently for at least 6 months prior to enrollment, participants should maintain the same stable intake pattern throughout the 24 week study period.
Disqualifiers
Diagnostic of knee osteoarthritis or any pathology or surgical intervention associated with the knee.
Hypersensitivity to any component of the supplement or the placebo
Chronic treatment with analgesic or anti-inflammatory (NSAIDs and corticosteroids families) drugs
Treatment with any type of collagen supplement
Trial design
Treatments tested in this trial
- Native type II collagen (Collavant® n2)
- Placebo
Treatment groups
Sponsors and collaborators
Bioiberica
Lead sponsor
Universidad Politecnica de Madrid
Collaborator